
Cat. #153819
Anti-eAg Antibody from X63 Fused CD19 B Cell Hybridoma (F8)
Cat. #: 153819
Unit size: 100 ug
Availability: 3-4 weeks
Target: Enteroantigen
Class: Monoclonal
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Anders Elm Pedersen ; Mogens H Claesson
Institute: University of Copenhagen
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-eAg Antibody from X63 Fused CD19 B Cell Hybridoma (F8)
- Research fields: Other
- Clone: F8
- Class: Monoclonal
- Conjugation: Unconjugated
- Description: Regulatory B cells (Bregs) have been shown to play a role in inflammatory bowel disease (IBD) in humans, as B cell depletion in patients with IBD tends to aggravate the disease. Furthermore it has been demonstrated that co-transfer of eAg-exposed B cells improves symptoms of experimental colitis in the T cell transfer model of colitis. This eAg-specific B cell hybridoma offers a unique tool to investigate the immune response towards eAgÄËĂÂĂÂs in experimental colitis, and potentially,...
Target Details
- Target: Enteroantigen
- Target background: Regulatory B cells (Bregs) have been shown to play a role in inflammatory bowel disease (IBD) in humans, as B cell depletion in patients with IBD tends to aggravate the disease. Furthermore it has been demonstrated that co-transfer of eAg-exposed B cells improves symptoms of experimental colitis in the T cell transfer model of colitis. This eAg-specific B cell hybridoma offers a unique tool to investigate the immune response towards eAgÄËĂÂĂÂs in experimental colitis, and potentially,...
Handling
- Format: Liquid
- Concentration: 0.9-1.1mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Dry ice
References
- In vitro cloning and regulatory potential of B cell hybridomas secreting entero-antigen specific antibody.
![Anti-CAR Whitlow Linker [1C3C3]](https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-300x322.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-280x300.jpg 280w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-954x1024.jpg 954w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-768x824.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 1193w)

![Anti-CAR Whitlow Linker [1B4A1]](https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-300x396.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-227x300.jpg 227w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-776x1024.jpg 776w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-768x1013.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 970w)



